Premium
Nine weeks of bedtime diazoxide is well tolerated and improves β‐cell function in subjects with Type 2 diabetes
Author(s) -
Qvigstad E.,
Kollind M.,
Grill V.
Publication year - 2004
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1046/j.1464-5491.2003.01091.x
Subject(s) - diazoxide , bedtime , medicine , endocrinology , metformin , type 2 diabetes , glucagon , placebo , insulin , diabetes mellitus , alternative medicine , pathology
Aims To test whether a bedtime dose of diazoxide can improve daytime β‐cell function without side‐effects in Type 2 diabetes. Methods A double‐blind randomized study was performed in 27 Type 2 diabetic subjects (17 male, 10 female) who were treated with bedtime insulin and metformin. Subjects received either bedtime diazoxide, 100 mg, or placebo for 9 weeks. Duplicate C‐peptide glucagon tests were performed before and in the last days of intervention. Results No side‐effects of diazoxide were detected. Treatment with diazoxide did not incur any increase in bedtime insulin. C‐peptide responses to glucagon tended to increase: 0.15 ± 0.06 nmol/l vs. −0.01 ± 0.04 nmol/l for placebo, P < 0.06 for difference. Corresponding effects on insulin were 66.2 ± 41.7 pmol/l for diazoxide vs. −84.2 ± 51.5 for placebo, P < 0.03. Treatment with diazoxide decreased fasting glucagon levels by 41% vs. placebo, P < 0.03. Glycated haemoglobin (HbA 1c ) levels were not affected, whereas levels of blood glucose post breakfast were higher during diazoxide (1.34 ± 0.43 mmol/l, P < 0.01 vs. placebo). Conclusions Bedtime treatment with diazoxide in Type 2 diabetic subjects on bedtime insulin and metformin has no significant side‐effects, does not increase bedtime insulin supplementation, tends to ameliorate β‐cell function but fails to improve metabolic control.